No alterations of brain GABA after 6 months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1480-3. doi: 10.1016/j.pnpbp.2010.08.007. Epub 2010 Aug 19.

Abstract

We investigated the effects of atypical antipsychotic drugs on GABA concentrations in early-stage, first-episode schizophrenia patients. Sixteen (8 males, 8 females; age, 30±11 years old) patients were followed up for six months. We also included 18 sex- and age-matched healthy control subjects. All patients were treated with atypical antipsychotic drugs (5 patients with risperidone, 5 patients with olanzapine, 4 patients with aripiprazole, and 2 patients with quetiapine). In all three regions measured (frontal lobe, left basal ganglia, and parieto-occipital lobe), no differences in GABA concentrations were observed in a comparison of pre-treatment levels and those six months after treatment. These results suggest that relatively short-term treatment with atypical antipsychotic drugs may not affect GABAergic neurotransmission; however, it is also possible that such treatment prevents further reductions in brain GABA levels in people with early-stage, first-episode schizophrenia.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antipsychotic Agents / administration & dosage*
  • Antipsychotic Agents / classification
  • Brain / drug effects*
  • Brain / metabolism*
  • Drug Administration Schedule
  • Early Diagnosis
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Schizophrenia / diagnosis
  • Schizophrenia / drug therapy*
  • Schizophrenia / metabolism*
  • Time Factors
  • Treatment Outcome
  • Young Adult
  • gamma-Aminobutyric Acid / metabolism*

Substances

  • Antipsychotic Agents
  • gamma-Aminobutyric Acid